Page 1 | Search Results | Blood | American Society of Hematology

1-20 of 37

Sort by

Sort Order Select

Journal Articles

Asciminib as initial therapy with addition of lower dose tyrosine kinase inhibitors (TKIs) for patients with chronic myeloid leukemia who do not achieve optimal response or a deep molecular remission

James Thompson, Lisa Rein, Michael Mauro, Srinivas Tantravahi, Jay Yang, Arielle Baim, Sonia Maldonado-Schmidt, Claire Olig, Kathryn Flynn, Yan Gao, Jerald Radich, Ehab Atallah, Jorge Cortes

Blood (2025) 146 (Supplement 1): 7311.

https://doi.org/10.1182/blood-2025-7311

Published: 2025

Journal Articles

Real world outcomes of patients with CML-CP treated with tyrosine kinase inhibitors from the h. jean khoury cure CML consortium (HJKC3)

Ehab Atallah, Emily Giever, Jorge Cortes, Ryan Conrardy, Lisa Rein, Arielle Baim, Idayat Akinola, James Thompson, Yan Gao, Richard Larson, Ravi Bhatia, B. Douglas Smith, Kathryn Flynn

Blood (2025) 146 (Supplement 1): 2844.

https://doi.org/10.1182/blood-2025-2844

Published: 2025

Journal Articles

A multicenter, single-arm study of camrelizumab combined with rituximab followed by R-CHOP as first-line treatment for young patients with primary extranodal diffuse large B-cell lymphoma: The credit trial

Yan Gao, Xue-Ping Li, Xuan-Ye Zhang, Xiaoxiao Wang, Qichun Cai, Bing BAI, Li-Qin Ping, Ji-Chen Hong, Huiqiang Huang

Blood (2025) 146 (Supplement 1): 5517.

https://doi.org/10.1182/blood-2025-5517

Published: 2025

Journal Articles

Long-term outcomes of a novel initial regimen: Rituximab plus pegylated interferon α-2b in untreated advanced indolent B-cell lymphoma – 5-year follow-up of the ripple study

Yan Gao, Li-Qin Ping, Jianqiu Wu, Yunhong Huang, Hui Zhou, Ru Feng, Huiqiang Huang

Blood (2025) 146 (Supplement 1): 5375.

https://doi.org/10.1182/blood-2025-5375

Published: 2025

Journal Articles

Lymphodepletion-free jl-lightning CAR-T targeting CD19/CD22/BCMA achieved 100% CR in 3 Relapsed/Refractory B-NHL patients: A lymphodepletion regimen comparison study

Jinxing Lou, Yan Sun, Shuya Wang, Feiyun Ma, Hongfan Zhu, Xinhong Guan, Zhicai Lin, Yan Gao, Mengxin Xia, Zhifeng Miao, Lijie Rong, Haizhong Zhong, Wenfeng Xu, Yi Liu, Qijun Qian

Blood (2025) 146 (Supplement 1): 4168.

https://doi.org/10.1182/blood-2025-4168

Published: 2025

Journal Articles

The single-cell atlas of bone marrow B cells reveals defective central B-cell tolerance in immune thrombocytopenia

Zi Sheng, Nan Jiang, Yan Gao, Yuhan Zhang, Xiaoyu Zhang, Nailin Li, Qi Feng, Yanqi Zhang, Limei Wang, John W. Semple, Shuwen Wang, Song Li, Jun Peng

Blood blood.2025028960.

https://doi.org/10.1182/blood.2025028960

Published: 2025

Includes: Supplemental data

Journal Articles

Single-cell epigenetic and clonal analysis decodes disease progression in pediatric acute myeloid leukemia

Boyu Cui, Lanlan Ai, Minghui Lei, Yongjuan Duan, Chao Tang, Jingliao Zhang, Yan Gao, Xuan Li, Caiying Zhu, Yingchi Zhang, Xiaofan Zhu, Tomoya Isobe, Wenyu Yang, Berthold Göttgens, Ping Zhu

Blood (2025) 145 (11): 1211–1224.

https://doi.org/10.1182/blood.2024025618

Published: 2025

Includes: Supplemental data

Journal Articles

Combination of Mitoxantrone Hydrochloride Liposome with Tislelizumab in Patients with Relapsed or Refractory NK/T Cell Lymphoma: A Phase Ib/Ⅱ Study

Blood (2024) 144 (Supplement 1): 4450.

https://doi.org/10.1182/blood-2024-209224

Published: 2024

Journal Articles

Decitabine Plus All- Trans Retinoic Acid Versus Decitabine Monotherapy for Myelodysplastic Syndromes with Excess Blasts: A Multicentre, Randomized Controlled Trial

Blood (2024) 144 (Supplement 1): 663.

https://doi.org/10.1182/blood-2024-200433

Published: 2024

Journal Articles

Safety, Efficacy, and Pharmacokinetics of Unecritinib (TQ-B3101) in Pediatric Patients with Relapsed/Refractory Anaplastic Lymphoma Kinase Positive Anaplastic Large Cell Lymphoma: A Phase I Study

Suying Lu, Junting Huang, Ruiqing Cai, Yan Gao, Jia Zhu, Juan Wang, Yi Que, Zi-Jun Zhen, Feifei Sun, Huiqiang Huang, Yizhuo Zhang

Blood (2024) 144 (Supplement 1): 3072.

https://doi.org/10.1182/blood-2024-209718

Published: 2024

Journal Articles

First Results of Asciminib As Initial Therapy with Addition of Lower Dose Tyrosine Kinase Inhibitors for Patients with Chronic Myeloid Leukemia Who Do Not Achieve a Deep Molecular Remission (ALERT CML) from the H Jean Khoury Cure CML Consortium (HJKC3)

Jorge E. Cortes, Michael J. Mauro, Alexis Visotcky, Srinivas K Tantravahi, James E Thompson, Jay Yang, Arielle Baim, Yan Gao, Sonia Maldonado-Schmidt, Claire Olig, Kathryn E. Flynn, Jerald P. Radich, Ehab L. Atallah

Blood (2024) 144 (Supplement 1): 6601.

https://doi.org/10.1182/blood-2024-207884

Published: 2024

Journal Articles

Selinexor Combined with Tislelizumab in Patients with Relapsed or Refractory Extranodal NK/T-Cell Lymphoma (R/R ENKTL): Preliminary Results of Arm C, from a Multicenter, Single-Arm, Phase I/II Study, Touch

Rong Tao, Chuanxu Liu, Yan Gao, Yang Yu, Zhi Guo, Jun Zhao, Huiqiang Huang

Blood (2024) 144 (Supplement 1): 4448.

https://doi.org/10.1182/blood-2024-206554

Published: 2024

Journal Articles

High-Dose Methotrexate, Ibrutinib and Temozolomide (MIT) for the Treatment of Newly Diagnosed Primary Central Nervous System Lymphoma: A Multi-Center Prospective Phase II Study

Liqin Ping, Xiaoxiao Wang, Yan Gao, Bing Bai, He Huang, Linbo Cai, Hui Zhou, Changguo Shan, Zhiming Li, Mingyao Lai, Haixia He, Cheng Huang, Haoqing Chen, Ru Feng, Huiqiang Huang

Blood (2023) 142 (Supplement 1): 3086.

https://doi.org/10.1182/blood-2023-185212

Published: 2023

Journal Articles

The Lymphocyte Subsets Activation Profiles in Peripheral Blood May Contribute to the Diagnosis of Natural Killer/T-Cell Lymphoma-Associated Hemophagocytic Lymphohistiocytosis

Yanxia He, Yan Gao, Xiaoxiao Wang, Bing Bai, Zhiming Li, Haixia He, Liqin Ping, Cheng Huang, Haoqing Chen, Huiqiang Huang

Blood (2023) 142 (Supplement 1): 6218.

https://doi.org/10.1182/blood-2023-186496

Published: 2023

Journal Articles

HJKC3-0006: Outcome of Patients with CML Treated on Second Line or Later Therapy in Routine Clinical Practice

Blood (2023) 142 (Supplement 1): 7420.

https://doi.org/10.1182/blood-2023-179963

Published: 2023

Journal Articles

HJKC3-007: Outcomes of Patients with Chronic Myeloid Leukemia in Chronic Phase Treated with Asciminib and Other Tyrosine Kinase Inhibitors in Routine Clinical Practice

Blood (2023) 142 (Supplement 1): 7434.

https://doi.org/10.1182/blood-2023-188683

Published: 2023

Journal Articles

Frontline Treatment with Zanubrutinib Plus Rituximab (ZR) Followed By Short Course R-Dhaox Shows Potent Efficacy in Patients with Mantle Cell Lymphoma (MCL) - Preliminary Results of Phase II CHESS Clinical Trial

Qingqing Cai, Yi Xia, Panpan Liu, Yuchen Zhang, Huiqiang Huang, Yan Gao, Guowei Li, Xiuhua Sun, Xueyi Pan

Blood (2022) 140 (Supplement 1): 9356–9357.

https://doi.org/10.1182/blood-2022-166237

Published: 2022

Journal Articles

A Prospective Study of Methotrexate in Combination with Ibrutinib and Temozolomide (MIT) in Newly Diagnosed Primary CNS Lymphoma

Xiaoxiao Wang, Changguo Shan, He Huang, Zhiming Li, Hui Zhou, Yan Gao, Shanshan Yu, Xiaoyu Hong, Mingyao Lai, Chao Yang, Yang Shao, Linbo Cai, Huiqiang Huang

Blood (2022) 140 (Supplement 1): 6606–6607.

https://doi.org/10.1182/blood-2022-169608

Published: 2022

Journal Articles

XPO1 Inhibitor (ATG-010) Plus GemOx Regimen for Heavily Pretreated Patients with Relapsed or Refractory (R/R) T and NK-Cell Lymphoma：Updates of the Phase Ib Touch Study

Huiqiang Huang, Yan Gao, Huilai Zhang, Keshu Zhou, Jianqiu Wu, Zhen Cai, Hongmei Jing, LEI Fan, Sai Lou, Yizhou Fei, Aihua Wang, Kevin Lynch

Blood (2022) 140 (Supplement 1): 6554–6555.

https://doi.org/10.1182/blood-2022-165797

Published: 2022

Journal Articles

XPO1 Inhibitor (ATG-010) Plus Chemotherapy per Investigator's Choice for Heavily Pretreated Patients with Relapsed or Refractory (R/R) Peripheral T-Cell Lymphoma (PTCL) and Extranodal NK/T-Cell Lymphoma (ENKTL)：Preliminary Results from a Multicenter, Single-Arm, Phase Ib Study (TOUCH Trial)

Huiqiang Huang, Yan Gao, Huilai Zhang, Keshu Zhou, Jianqiu Wu, Zhen Cai, Hongmei Jing, Lei Fan, Sai Lou, Yizhou Fei, Aihua Wang, Kevin Lynch

Blood (2021) 138 (Supplement 1): 2452.

https://doi.org/10.1182/blood-2021-147100

Published: 2021

Update search

NARROW

Publications

Format

Subjects

Article Type

Topics

Date

Availability

Asciminib as initial therapy with addition of lower dose tyrosine kinase inhibitors (TKIs) for patients with chronic myeloid leukemia who do not achieve optimal response or a deep molecular remission

Real world outcomes of patients with CML-CP treated with tyrosine kinase inhibitors from the h. jean khoury cure CML consortium (HJKC3)

A multicenter, single-arm study of camrelizumab combined with rituximab followed by R-CHOP as first-line treatment for young patients with primary extranodal diffuse large B-cell lymphoma: The credit trial

Long-term outcomes of a novel initial regimen: Rituximab plus pegylated interferon α-2b in untreated advanced indolent B-cell lymphoma – 5-year follow-up of the ripple study

Lymphodepletion-free jl-lightning CAR-T targeting CD19/CD22/BCMA achieved 100% CR in 3 Relapsed/Refractory B-NHL patients: A lymphodepletion regimen comparison study

The single-cell atlas of bone marrow B cells reveals defective central B-cell tolerance in immune thrombocytopenia

Single-cell epigenetic and clonal analysis decodes disease progression in pediatric acute myeloid leukemia

Combination of Mitoxantrone Hydrochloride Liposome with Tislelizumab in Patients with Relapsed or Refractory NK/T Cell Lymphoma: A Phase Ib/Ⅱ Study

Decitabine Plus All- Trans Retinoic Acid Versus Decitabine Monotherapy for Myelodysplastic Syndromes with Excess Blasts: A Multicentre, Randomized Controlled Trial

Safety, Efficacy, and Pharmacokinetics of Unecritinib (TQ-B3101) in Pediatric Patients with Relapsed/Refractory Anaplastic Lymphoma Kinase Positive Anaplastic Large Cell Lymphoma: A Phase I Study

First Results of Asciminib As Initial Therapy with Addition of Lower Dose Tyrosine Kinase Inhibitors for Patients with Chronic Myeloid Leukemia Who Do Not Achieve a Deep Molecular Remission (ALERT CML) from the H Jean Khoury Cure CML Consortium (HJKC3)

Selinexor Combined with Tislelizumab in Patients with Relapsed or Refractory Extranodal NK/T-Cell Lymphoma (R/R ENKTL): Preliminary Results of Arm C, from a Multicenter, Single-Arm, Phase I/II Study, Touch

High-Dose Methotrexate, Ibrutinib and Temozolomide (MIT) for the Treatment of Newly Diagnosed Primary Central Nervous System Lymphoma: A Multi-Center Prospective Phase II Study

The Lymphocyte Subsets Activation Profiles in Peripheral Blood May Contribute to the Diagnosis of Natural Killer/T-Cell Lymphoma-Associated Hemophagocytic Lymphohistiocytosis

HJKC3-0006: Outcome of Patients with CML Treated on Second Line or Later Therapy in Routine Clinical Practice

HJKC3-007: Outcomes of Patients with Chronic Myeloid Leukemia in Chronic Phase Treated with Asciminib and Other Tyrosine Kinase Inhibitors in Routine Clinical Practice

Frontline Treatment with Zanubrutinib Plus Rituximab (ZR) Followed By Short Course R-Dhaox Shows Potent Efficacy in Patients with Mantle Cell Lymphoma (MCL) - Preliminary Results of Phase II CHESS Clinical Trial

A Prospective Study of Methotrexate in Combination with Ibrutinib and Temozolomide (MIT) in Newly Diagnosed Primary CNS Lymphoma

XPO1 Inhibitor (ATG-010) Plus GemOx Regimen for Heavily Pretreated Patients with Relapsed or Refractory (R/R) T and NK-Cell Lymphoma：Updates of the Phase Ib Touch Study

XPO1 Inhibitor (ATG-010) Plus Chemotherapy per Investigator's Choice for Heavily Pretreated Patients with Relapsed or Refractory (R/R) Peripheral T-Cell Lymphoma (PTCL) and Extranodal NK/T-Cell Lymphoma (ENKTL)：Preliminary Results from a Multicenter, Single-Arm, Phase Ib Study (TOUCH Trial)

Email alerts

ASH Publications

American Society of Hematology

Update search

Email alerts

ASH Publications

American Society of Hematology

This Feature Is Available To Subscribers Only